IL (Interleukin)-1 Receptor Antagonist Increases Ang (Angiotensin [1-7]) and Decreases Blood Pressure in Obese Individuals.
Angiotensin I
/ metabolism
Antihypertensive Agents
/ pharmacology
Antirheumatic Agents
/ pharmacology
Blood Pressure
/ drug effects
Blood Pressure Determination
/ methods
Duration of Therapy
Female
Humans
Interleukin 1 Receptor Antagonist Protein
/ pharmacology
Male
Middle Aged
Obesity
/ immunology
Peptide Fragments
/ metabolism
Receptors, Interleukin-1
/ antagonists & inhibitors
Renin-Angiotensin System
/ drug effects
Vascular Resistance
/ drug effects
Vasodilator Agents
/ pharmacology
aldosterone
angiotensins
blood pressure
interleukins
peptides
Journal
Hypertension (Dallas, Tex. : 1979)
ISSN: 1524-4563
Titre abrégé: Hypertension
Pays: United States
ID NLM: 7906255
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
11
4
2020
medline:
10
4
2021
entrez:
11
4
2020
Statut:
ppublish
Résumé
IL (Interleukin)-1 antagonism decreases blood pressure in obese individuals. The underlying mechanisms are unknown. Based on experimental data, we hypothesized an effect of IL-1 antagonism via modulation of the renin-angiotensin-aldosterone system. In this explorative study, we examined shorter- (2 days) and longer-term effects (4 weeks) of IL-1 antagonism (anakinra/Kineret) on renin-angiotensin system peptide profiles and on hemodynamic parameters assessed by noninvasive measurement in obese (body mass index ≥30 kg/m
Identifiants
pubmed: 32275191
doi: 10.1161/HYPERTENSIONAHA.119.13982
doi:
Substances chimiques
Antihypertensive Agents
0
Antirheumatic Agents
0
Interleukin 1 Receptor Antagonist Protein
0
Peptide Fragments
0
Receptors, Interleukin-1
0
Vasodilator Agents
0
Angiotensin I
9041-90-1
angiotensin I (1-7)
IJ3FUK8MOF
Banques de données
ClinicalTrials.gov
['NCT02672592', 'NCT02227420']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM